J B Chemicals & Pharmaceuticals Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xmipooypw53gsbmwo5d92opq.pdf

Key Takeaways


Domestic Business: The Growth Engine

Chopra: "If you look at in a country like India, 10 crore plus people suffer from hypertension and one in four patients is undiagnosed. So, we have basically put the entire positioning of segmentation, targeting and positioning for all our different SKUs to different specialty for different indication."

CDMO Business: A Hiccup, Not a Reset

Khanna: "No, this is not related to any change in vendor, nothing of concern, just specific excipients got delayed... Overall, we see very strong traction for our CDMO business in H2."

International Business: A Transition Year


Margins & Capital Allocation


Levers for Future Growth

Chopra: "If you ask aspiration, we want to inch up in terms of where we want to be in terms of prescription, we want to be in top 10 by the way in terms of prescription."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic business growth12%-14% growth in H2 FY25; continue to outgrow marketH2 FY25
CDMO business recovery"Very high double digit growth rate to 20% plus" in H2; full year flattish over FY24H2 FY25 / FY25
Azmarda volume trajectoryReach 140,000-145,000 units; mid-teens growth thereafterFY25-end / beyond
Ophthalmology portfolio targetAchieve Rs. 185-190 crore; expand prescriber base to 16,000-17,000Next 12 months
International regulatory approvalsFirst set of 10 product approvals expectedSep/Oct CY25 (Q3/Q4 FY26)
CDMO revenue ambitionDouble business from ~$50 million to $100 million3-5 years
Operating EBITDA marginMaintain 26%-28% range; endeavor to be at higher endOngoing
Capex run-rateAnnual capex of Rs. 100-120 crore with 15-20% for growthOngoing

Key Metrics

MetricQ2 FY25
Revenue₹1,001 cr, +13% YoY
Domestic revenue₹588 cr, +22% YoY; 59% of H1 turnover
Domestic revenue excl. Ophthalmology+12.6% YoY
International revenue₹413 cr, +3% YoY
Gross margin66.2%, excl. Ophthalmology improved >150 bps YoY
Operating EBITDA (excl. ESOP)₹285 cr, +13% YoY; margin 28.4%
Net profit₹175 cr, +16% YoY
Operating EBITDA margin guidance26%–28%, maintained; endeavor to be at higher range
Domestic volume growth (excl. Ophthal)~5% vs IPM <1.5%
Domestic price growth (excl. Ophthal)~6%
IQVIA growth vs IPM (MAT Sep 24)11% vs IPM 7.6%
CDMO revenue deferredUS $2 mn deferred to Q3 FY25 due to material availability
CDMO H2 FY25 growth expectationVery high double digit, 20%+
CDMO medium-term aspiration$100 mn in 3–5 years, maintained
Azmarda monthly run rate125,000 units, ~₹6 cr monthly value; targeting 140,000–145,000 units by FY25-end
Razel franchisee growth (IQVIA MAT Sep 24)+28% YoY
Sporlac franchisee revenue (IQVIA MAT Sep 24)₹137 cr, 29% CAGR from ₹83 cr in MAT Sep 22
Cilacar and Cilacar-T volume growth (past 3 years)12%–14%
Ophthalmology portfolio quarterly run rate~₹48 cr, acquired at ~₹40 cr steady-state; targeting ₹185–₹190 cr
Ophthalmology prescriber coverage~13,500 ophthalmologists, expanding to 16,000–17,000 in 12 months
MR base2,300 including Ophthalmology; no additions planned in 12–18 months
MR productivity~₹11 lakh annually
Gross debt (30 Sep 2024)₹82 cr vs ₹358 cr on 31 Mar 2024
Finance costs₹2 cr vs ₹10 cr in Q2 FY24
MTM FOREX impact₹4 cr loss, primarily Ruble depreciation
Operating cash flow (H1 FY25)₹380 cr vs ₹421 cr in H1 FY24
Net CAPEX (H1 FY25)₹53 cr vs ₹93 cr in H1 FY24; full-year guidance ₹100+ cr
ESOP cost (Q2 FY25)₹14 cr; full-year expectation ~₹45 cr
India business H2 FY25 growth expectation12%–14%
International business FY25 growth expectationHigh single digit for full year, double digit in H2